India Eyes Global Tenders for Key Patented Drugs

The Indian government is contemplating the procurement of over 65 patented and proprietary medicines through global tenders. This strategic consideration is primarily aimed at bolstering the supply chain for central healthcare institutions, notably the armed forces' medical services and the Employees' State Insurance Corporation (ESIC).

The proposed tenders cover a range of essential drugs, including those for type-2 diabetes, obesity, and high cholesterol, where India currently has limited or no domestic manufacturing capacity. This initiative is particularly relevant as the government's public procurement policy typically favors local industries by prohibiting global tendering for procurements below ₹200 crore.

However, exemptions are permissible under circumstances of insufficient domestic supply or urgent public requirement. The Department of Pharmaceuticals has invited objections from local manufacturers regarding the inclusion of these formulations, signaling a deliberative approach to balancing national interests with patient access to vital medications.